Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese Population
- 1 June 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 20 (3) , 243-247
- https://doi.org/10.1097/00007691-199806000-00001
Abstract
Genotypings of two mutations (*2 and *3) in CYP2C19 and the amino acid variants (Arg144/Cys, Tyr358/Cys, Ile359/Leu, and Gly417/Asp) in CYP2C9 were carried out in 140 unrelated Japanese subjects. Thirty-three subjects (23.6%) were genotypically identified as poor metabolizers of CYP2C19, and the allele frequencies of theCYP2C19*2 and CYP2C19*3 were 0.35 and 0.11, respectively. The authors' findings are in agreement with the 18% to 23% prevalence of poor metabolizers in the Japanese populations previously phenotyped. InCYP2C9, all subjects were homozygous (CYP2C9*1) for Arg144, Tyr358, Ile359, and Gly417, except for five subjects (3.6%) who were heterozygous for the Leu359(CYP2C9*3). The frequencies of Arg144, Tyr358, Ile359, Leu359, and Gly417 variants were 1.0, 1.0, 0.982, 0.018, and 1.0, respectively. The low frequency of the Cys144 allele(CYP2C9*2) in the Japanese population is different from the frequency recently found in British subjects (allele frequency, 0.125 to 0.192). The results suggest that the known interindividual variations in theCYP2C9 sequence among Japanese subjects is small, and that Ile359/Leu is one possible site showing interracial polymorphism.Keywords
This publication has 23 references indexed in Scilit:
- Phenotyping of CYP2C19 with enantiospecific HPLCquantification of R- and S-mephenytoin and comparison with the intron4/exon5 G??? A-splice site mutationPharmacogenetics, 1995
- Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9Pharmacogenetics, 1994
- Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamilyBiochemical Journal, 1993
- Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9Biochemical and Biophysical Research Communications, 1991
- Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populationsEuropean Journal of Clinical Pharmacology, 1990
- Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin HydroxylatorsTherapeutic Drug Monitoring, 1990
- Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland ChineseClinical Pharmacology & Therapeutics, 1989
- Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotypeClinical Pharmacology & Therapeutics, 1989
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985
- Pharmacogenetics of tolbutamide metabolism in humansDiabetes, 1979